International Assets Investment Management LLC Acquires 1,138 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

International Assets Investment Management LLC increased its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 7,112.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,154 shares of the company’s stock after purchasing an additional 1,138 shares during the quarter. International Assets Investment Management LLC’s holdings in Prestige Consumer Healthcare were worth $83,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Opal Wealth Advisors LLC bought a new position in shares of Prestige Consumer Healthcare in the second quarter worth about $26,000. Quest Partners LLC raised its stake in Prestige Consumer Healthcare by 2,826.7% during the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after acquiring an additional 424 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Prestige Consumer Healthcare by 80.6% during the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock valued at $33,000 after purchasing an additional 208 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in Prestige Consumer Healthcare by 562.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after purchasing an additional 433 shares in the last quarter. Finally, Gladius Capital Management LP bought a new position in shares of Prestige Consumer Healthcare in the second quarter worth approximately $35,000. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on PBH. Jefferies Financial Group restated a “hold” rating and set a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. DA Davidson upped their price objective on Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.20.

Prestige Consumer Healthcare Trading Up 3.1 %

Shares of PBH stock opened at $80.07 on Friday. The company has a current ratio of 3.23, a quick ratio of 1.90 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $3.97 billion, a price-to-earnings ratio of 19.58, a price-to-earnings-growth ratio of 2.08 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a 12-month low of $56.61 and a 12-month high of $81.25. The stock’s 50-day moving average price is $72.43 and its 200-day moving average price is $69.78.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.86 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.55% and a net margin of 18.43%. The business had revenue of $267.10 million for the quarter, compared to the consensus estimate of $260.54 million. During the same quarter in the previous year, the company posted $1.06 EPS. The company’s revenue was down 4.4% compared to the same quarter last year. Equities research analysts predict that Prestige Consumer Healthcare Inc. will post 4.43 EPS for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.